Asrat Hailu Selected Research

Paromomycin (Paromomycin Sulfate)

11/2021	Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.
1/2021	Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
3/2017	Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
1/2012	Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
10/2010	Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
10/2010	Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Asrat Hailu Research Topics

Disease

34	Visceral Leishmaniasis (Kala Azar) 11/2021 - 01/2004
10	Infections 06/2022 - 07/2002
10	Leishmaniasis 01/2020 - 11/2004
6	Coinfection 01/2021 - 11/2010
4	Malaria 06/2022 - 11/2004
4	Onchocerciasis 01/2022 - 04/2012
3	Cutaneous Leishmaniasis 11/2020 - 01/2012
2	Renal Insufficiency (Renal Failure) 01/2019 - 01/2015
2	HIV Infections (HIV Infection) 01/2013 - 07/2011
2	Tuberculosis (Tuberculoses) 08/2012 - 07/2011
1	Falciparum Malaria (Plasmodium falciparum Malaria) 05/2022
1	Glucosephosphate Dehydrogenase Deficiency 01/2022
1	Hemolysis 01/2022
1	Acute malaria 01/2022
1	Parasitic Diseases (Parasitic Disease) 01/2022
1	Parasitemia 01/2021
1	Pain (Aches) 01/2021
1	Neglected Diseases 01/2020
1	Loiasis 07/2019
1	Vivax Malaria 01/2019
1	Chagas Disease (American Trypanosomiasis) 01/2019
1	Inflammation (Inflammations) 07/2017
1	Hypokalemia 10/2016
1	Toxoplasmosis 05/2015
1	Pneumonia (Pneumonitis) 01/2015
1	Elephantiasis 01/2015
1	Body Weight (Weight, Body) 01/2014
1	Acquired Immunodeficiency Syndrome (AIDS) 07/2011
1	Echinococcosis (Hydatid Cysts) 03/2011
1	Schistosomiasis mansoni 02/2007
1	Lymphangitis 03/2006
1	Lymphopenia (Lymphocytopenia) 11/2005
1	Asymptomatic Infections 11/2005

Drug/Important Bio-Agent (IBA)

9	Pharmaceutical PreparationsIBA 01/2022 - 01/2014
7	AntigensIBA 03/2016 - 03/2006
6	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 11/2021 - 10/2010
6	Antimony Sodium Gluconate (Sodium, Stibogluconate)IBA 01/2021 - 11/2010
6	liposomal amphotericin B FDA Link 01/2019 - 03/2011
5	CytokinesIBA 01/2021 - 11/2004
5	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 03/2013
5	ArginaseIBA 01/2013 - 05/2008
4	Ivermectin (Mectizan)FDA Link 01/2022 - 04/2012
4	AntibodiesIBA 01/2021 - 05/2015
3	Primaquine FDA Link 05/2022 - 01/2019
3	Interleukin-10 (Interleukin 10)IBA 01/2021 - 02/2007
3	leishmaninIBA 01/2019 - 11/2005
3	miltefosine (Impavido)IBA 01/2019 - 01/2016
3	Pentamidine (NebuPent)FDA LinkGeneric 01/2019 - 01/2015
3	InterferonsIBA 03/2016 - 11/2004
3	Arginine (L-Arginine)FDA Link 01/2012 - 05/2008
2	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 01/2022 - 01/2019
2	Biological ProductsIBA 01/2019 - 09/2014
2	EnzymesIBA 01/2013 - 03/2011
2	CXC ChemokinesIBA 07/2011 - 11/2004
2	Interleukin-4 (Interleukin 4)IBA 02/2007 - 11/2005
1	InsecticidesIBA 06/2022
1	Histidine (L-Histidine)FDA Link 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	tafenoquineIBA 01/2022
1	alpha-AmylasesIBA 01/2021
1	Transaminases (Aminotransferases)IBA 01/2021
1	Growth InhibitorsIBA 01/2020
1	Recombinant ProteinsIBA 12/2018
1	Kinetoplast DNA (kDNA)IBA 10/2015
1	ClayIBA 01/2015
1	Toll-Like Receptor 3IBA 04/2014
1	SugarsIBA 06/2013
1	Dry IceIBA 06/2013
1	Human immunodeficiency virus 1 p16 proteaseIBA 03/2013
1	Protease Inhibitors (Protease Inhibitor)IBA 03/2013
1	Tuberculin (PPD)IBA 08/2012
1	GoldIBA 08/2012
1	Indicators and Reagents (Reagents)IBA 04/2012
1	HLA-DR Antigens (HLA-DR)IBA 07/2011
1	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 07/2011
1	6-carboxyfluorescein diacetateIBA 07/2011
1	EstersIBA 07/2011
1	Chemokine CCL5IBA 07/2011
1	Chemokine CXCL12IBA 07/2011
1	CC ChemokinesIBA 07/2011
1	ChemokinesIBA 07/2011
1	Chemokine CCL4IBA 07/2011
1	Chemokine CCL3IBA 07/2011
1	OilsIBA 04/2011
1	ImmunosorbentsIBA 03/2011
1	Meglumine AntimoniateIBA 11/2010
1	SodiumIBA 11/2010
1	gluconic acid (gluconate)FDA LinkGeneric 11/2010
1	AntimonyIBA 11/2010
1	LatexIBA 09/2007
1	Triose-Phosphate Isomerase (Triosephosphate Isomerase)IBA 05/2007
1	RNA (Ribonucleic Acid)IBA 05/2007
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2007
1	Interleukin-12 (IL 12)IBA 02/2007
1	IonomycinIBA 11/2005
1	Interleukin-15 (Interleukin 15)IBA 11/2004

Therapy/Procedure

3	Therapeutics 01/2019 - 07/2009
2	Mass Drug Administration 01/2022 - 07/2019
1	Aftercare (After-Treatment) 01/2021
1	Prenatal Care (Care, Prenatal) 05/2015